VeracyteVCYT
VCYT
About: Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder). In addition, its Percepta Nasal Swab test is being run in CLIA labs in support of clinical studies.
Employees: 824
0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
1,042% more call options, than puts
Call options by funds: $8.4M | Put options by funds: $736K
116% more first-time investments, than exits
New positions opened: 54 | Existing positions closed: 25
25% more funds holding in top 10
Funds holding in top 10: 4 [Q3] → 5 (+1) [Q4]
17% more capital invested
Capital invested by funds: $2.78B [Q3] → $3.25B (+$471M) [Q4]
8% more funds holding
Funds holding: 290 [Q3] → 314 (+24) [Q4]
0.52% more ownership
Funds ownership: 106.74% [Q3] → 107.26% (+0.52%) [Q4]
14% less repeat investments, than reductions
Existing positions increased: 102 | Existing positions reduced: 119
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$37
25%
upside
Avg. target
$42
41%
upside
High target
$45
51%
upside
5 analyst ratings
5 positive
100%
0 neutral
0%
0 negative
0%
UBS Lu Li 25% 1-year accuracy 1 / 4 met price target | 41%upside $42 | Buy Maintained | 8 May 2025 |
Needham Mike Matson 35% 1-year accuracy 39 / 111 met price target | 38%upside $41 | Buy Maintained | 8 May 2025 |
Guggenheim Subbu Nambi 26% 1-year accuracy 6 / 23 met price target | 25%upside $37 | Buy Maintained | 9 Apr 2025 |
Stephens & Co. Mason Carrico 11% 1-year accuracy 3 / 27 met price target | 51%upside $45 | Overweight Reiterated | 26 Mar 2025 |
Craig-Hallum John Wilkin 33% 1-year accuracy 1 / 3 met price target | 51%upside $45 | Buy Initiated | 20 Mar 2025 |
Financial journalist opinion
Based on 12 articles about VCYT published over the past 30 days
Positive
Zacks Investment Research
2 days ago
Veracyte Stock Gains on Q1 Earnings and Revenue Beat, Gross Margin Up
VCYT registers robust growth from its market-leading Decipher Prostate and Afirma tests in the first quarter of 2025.
Positive
Zacks Investment Research
3 days ago
What Makes Veracyte (VCYT) a New Buy Stock
Veracyte (VCYT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Neutral
Seeking Alpha
4 days ago
Veracyte, Inc. (VCYT) Q1 2025 Earnings Call Transcript
Veracyte, Inc. (NASDAQ:VCYT ) Q1 2025 Earnings Call May 7, 2025 4:30 PM ET Company Participants Shayla Gorman - Investor Relations Marc Stapley - Chief Executive Officer Rebecca Chambers - Chief Financial Officer John Leite - Chief Commercial Officer Conference Call Participants Subbu Nambi - Guggenheim Securities Andrew Brackmann - William Blair Puneet Souda - Leerink Partners Colleen Babington - Wolfe Research Tejas Savant - Morgan Stanley Thomas DeBourcy - Nephron Research Sung Ji Nam - Scotiabank Operator Good day and thank you for standing by. Welcome to the Veracyte First Quarter 2025 Financial Results Webcast.
Positive
Zacks Investment Research
4 days ago
Veracyte (VCYT) Q1 Earnings and Revenues Beat Estimates
Veracyte (VCYT) came out with quarterly earnings of $0.31 per share, beating the Zacks Consensus Estimate of $0.20 per share. This compares to loss of $0.02 per share a year ago.
Neutral
Business Wire
4 days ago
Veracyte Announces First Quarter 2025 Financial Results
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced financial results for the first quarter ended March 31, 2025. "We started 2025 with the eleventh consecutive quarter of 20% or more testing volume growth, driven by strong Decipher and Afirma demand,” said Marc Stapley, Veracyte's chief executive officer. “With solid Q1 results and Decipher now available for metastatic prostate cancer patients, we are well positione.
Neutral
Business Wire
2 weeks ago
Veracyte Announces Expanded Availability of Decipher Prostate Test to Patients with Metastatic Prostate Cancer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte Announces Expanded Availability of Decipher Prostate Test to Patients with Metastatic Prostate Cancer.
Neutral
Business Wire
2 weeks ago
Veracyte Announces Multiple Abstracts Demonstrating Power of Decipher Testing To Fuel New Prostate and Bladder Cancer Insights Will Be Presented at AUA Annual Meeting
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte Announces Multiple Abstracts Demonstrating Power of Decipher Testing Will Be Presented at AUA Annual Meeting.
Neutral
Business Wire
2 weeks ago
Veracyte Announces Decipher Prostate Genomic Classifier Results are Linked to Real-World Data in National Cancer Institute's SEER Specialized Database Release
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte Announces Decipher Prostate Genomic Classifier Results are Linked to National Cancer Institute's SEER Specialized Database Release.
Positive
Investors Business Daily
3 weeks ago
The Blood Test Revolution: It's A New Day In Cancer. Guardant, Natera And Exact Are Here For It.
A revolution in oncology could help the 18 million cancer survivors in the U.S. and bolster Guardant Health, Natera and Exact Sciences.
Positive
Zacks Investment Research
3 weeks ago
Should You Continue to Hold Veracyte Stock in Your Portfolio?
Strength in the Afirma and Decipher franchises continues to bode well for VCYT stock.
Charts implemented using Lightweight Charts™